151 related articles for article (PubMed ID: 25568664)
1. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML.
Oancea C; Rüster B; Brill B; Roos J; Heinssmann M; Bug G; Mian AA; Guillen NA; Kornblau SM; Henschler R; Ruthardt M
Genes Cancer; 2014 Nov; 5(11-12):378-92. PubMed ID: 25568664
[TBL] [Abstract][Full Text] [Related]
2. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
[TBL] [Abstract][Full Text] [Related]
3. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
4. Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells.
Zheng X; Oancea C; Henschler R; Ruthardt M
Int J Oncol; 2009 Jun; 34(6):1521-31. PubMed ID: 19424569
[TBL] [Abstract][Full Text] [Related]
5. Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.
Steinert G; Oancea C; Roos J; Hagemeyer H; Maier T; Ruthardt M; Puccetti E
PLoS One; 2011; 6(7):e22540. PubMed ID: 21811629
[TBL] [Abstract][Full Text] [Related]
6. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation.
Oancea C; Rüster B; Henschler R; Puccetti E; Ruthardt M
Leukemia; 2010 Nov; 24(11):1910-9. PubMed ID: 20827285
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
Ageberg M; Drott K; Olofsson T; Gullberg U; Lindmark A
Genes Chromosomes Cancer; 2008 Apr; 47(4):276-87. PubMed ID: 18181180
[TBL] [Abstract][Full Text] [Related]
8. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
9. A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.
Hao Q; Zhang Q; Li C; Wei S; Li Q; Song Y; Mi Y
Oncol Lett; 2017 Dec; 14(6):7021-7024. PubMed ID: 29344131
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
11. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
[TBL] [Abstract][Full Text] [Related]
12. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
Qin H; Malek S; Cowell JK; Ren M
Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
[TBL] [Abstract][Full Text] [Related]
13. Targeting of leukemia-initiating cells in acute promyelocytic leukemia.
Testa U; Lo-Coco F
Stem Cell Investig; 2015; 2():8. PubMed ID: 27358876
[TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.
Puccetti E; Ruthardt M
Leukemia; 2004 Jul; 18(7):1169-75. PubMed ID: 15103387
[TBL] [Abstract][Full Text] [Related]
15. NUP214 in Leukemia: It's More than Transport.
Mendes A; Fahrenkrog B
Cells; 2019 Jan; 8(1):. PubMed ID: 30669574
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
17. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
20. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.
Ommen HB; Touzart A; MacIntyre E; Kern W; Haferlach T; Haferlach C; Tobal K; Hokland P; Schnittger S
Eur J Haematol; 2015 Nov; 95(5):436-41. PubMed ID: 25605311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
